Search Results

ZMC1 2 mg  | 97.48%

TargetMol

NSC319726, a mutant p53R175 reactivator, suppresses growth of fibroblasts that expresses the p53R175 mutation (IC50 = 8 nM).

More Information Supplier Page

ML141 100 mg  | 99.77%

TargetMol

ML141 is an effective, specific and reversible non-competitive inhibitor of Rho family GTPase cdc42 (IC50: 200 nM).

More Information Supplier Page

ML141 2 mg  | 99.77%

TargetMol

ML141 is an effective, specific and reversible non-competitive inhibitor of Rho family GTPase cdc42 (IC50: 200 nM).

More Information Supplier Page

Apabetalone 25 mg  | 99.00%

TargetMol

RVX-208, an effective BET bromodomain inhibitor, has been investigated for the treatment of diabetes, atherosclerosis, and coronary artery disease.

More Information Supplier Page

Apabetalone 100 mg  | 99.00%

TargetMol

RVX-208, an effective BET bromodomain inhibitor, has been investigated for the treatment of diabetes, atherosclerosis, and coronary artery disease.

More Information Supplier Page

IOWH-032 25 mg  | 98.00%

TargetMol

IOWH032, a synthetic CFTR inhibitor, has been investigated for the treatment of cholera, diarrhea, and secretory diarrhea.

More Information Supplier Page

Binimetinib 200 mg  | Purity Not Available

TargetMol

Binimetinib (MEK162, ARRY-162, ARRY-438162) is an orally available inhibitor of MEK1/2 (IC50: 12 nM) in a cell-free assay.

More Information Supplier Page

Binimetinib 100 mg  | Purity Not Available

TargetMol

Binimetinib (MEK162, ARRY-162, ARRY-438162) is an orally available inhibitor of MEK1/2 (IC50: 12 nM) in a cell-free assay.

More Information Supplier Page